IRVING, Texas–(BUSINESS WIRE)–Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter Highlights, year over year: Revenue of $44.5 million, an 18.5% increase. Net income of $12.8 million and fully diluted GAAP earnings per share of $0.18. Adjusted EBITDA of $13.1 million, a 40% increase.1 Full Year 2022 Highli My Business Wire News
